Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 921 matching trials from the live ClinicalTrials.gov search.
Conditions
Refractory Solid Tumors
Interventions
Eribulin, Irinotecan, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Combination Product
Lead sponsor
Emory University
Other
Eligibility
12 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Conditions
Colorectal Carcinoma
Interventions
VELCADE TM (bortezomib) for Injection, or PS-341
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Pine Bluff, Arkansas + 18 more
Conditions
Leukemia, Lymphoma
Interventions
Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Colorectal Cancer
Interventions
trastuzumab, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Conditions
Metastatic Solid Tumors
Interventions
Sacituzumab Govitecan-hiy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Newark, Delaware + 11 more
Conditions
Colon Cancer, Pancreas Cancer, Digestive Cancer
Interventions
CEND-1, Panitumumab, Folfirinox
Drug
Lead sponsor
Anup Kasi
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri
Conditions
Advanced Gastrointestinal Tumors
Interventions
TAS-102, CPT-11, Bevacizumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York + 1 more
Conditions
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Onivyde, Talazoparib, Temozolomide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 30 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Conditions
Lung Cancer
Interventions
celecoxib, docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Joliet, Illinois
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Colorectal Neoplasms
Interventions
Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Irinotecan
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
71
States / cities
Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclosporine, irinotecan hydrochloride, phenobarbital
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Solid Tumors
Interventions
EZN-2208
Drug
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy, Irinotecan, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
31
States / cities
Duarte, California • Los Angeles, California • Orange, California + 25 more
Conditions
Pancreatic Adenocarcinoma
Interventions
5 Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Colorectal Cancer
Interventions
Panitumumab, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Orlando, Florida + 11 more
Conditions
Glioblastoma Multiforme, Glioblastoma, GBM
Interventions
Nanoliposomal Irinotecan, Temozolomide
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Colorectal Cancer
Interventions
IMMU-130
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
Drug · Biological
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
185
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
Conditions
Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico